Answers are grounded in this paper and cite their sources.
Introduction Diabetic macular edema (DME) is a common cause of vision loss in patients with diabetic retinopathy and occurs in a substantial proportion of patients with long-standing diabetes. Intravitreal anti-VEGF agents have revolutionized the treatment of DME and become the standard of care for managing macular edema.Areas covered A literature search was performed in PubMed for all articles in the past ten years that involve DME and at least one anti-VEGF agent, focusing mainly on randomized clinical trials. We provide an overview of three anti-VEGF agents – bevacizumab, ranibizumab, and aflibercept – and summarize the key evidence regarding their safety and efficacy. In addition, we discuss new anti-VEGF therapies that are currently being developed for DME and other retinal vascular diseases.Expert opinion There is level 1 evidence to demonstrate that intravitreal anti-VEGF agents are safe and effective for the treatment of DME. Anti-VEGF therapy improves visual acuity and decreases retinal thickness associated with DME. Novel anti-VEGF agents and alternative drug delivery systems are currently being investigated as additional therapies for DME.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: